Here are the results of Jefferies & Company Inc.’s in-depth investigation into Fresenius SE stock.
The analysis firm Jefferies has left Fresenius at “Buy” with a price target of 55 euros. According to an expert assessment, the German hospital system urgently needs to reduce its capacity, wrote James Vane-Tempest in a comment on Monday. At least 300 of the 1,800 clinics could be closed without affecting patient care in order to save costs. However, relocating treatments out of the clinics would encounter significant hurdles. Hospital groups like Fresenius, which could form regional clusters, could be relative winners from such a change.
Between price target and reality: The Fresenius SE share in detail on the day of the analysis
At 12:06 p.m., Fresenius SE shares posted gains. In the XETRA session, the stock rose by 0.8 percent to EUR 48.02. This means that the shareholding still has room for improvement of 14.54 percent compared to the stated price target. Most recently, 129,676 Fresenius SE shares changed hands via XETRA. The share has climbed 46.6 percent since the beginning of 2025. Fresenius SE is expected to provide investors with an insight into the quarterly balance sheet for Q3 2025 on November 5th, 2025.
NEW YORK (dpa-AFX Analyzer) / editorial team finanzen.net
Publication of the original study: October 17, 2025 / 1:03 p.m. / ET First distribution of the original study: October 19, 2025 / 7:00 p.m. / ET
Note: Information on the disclosure obligation in the event of conflicts of interest within the meaning of Section 85 Para. 1 WpHG, Art. 20 Regulation (EU) 596/2014 for the analyst firm mentioned can be found at http://web.dpa-afx.de/offenlegenspflicht/offenlegens_pflicht.html.
Selected leverage products on Fresenius
With knock-outs, speculative investors can participate disproportionately in price movements. Simply select the lever you want and we will show you suitable open-end products on Fresenius
The leverage must be between 2 and 20
Advertising